Amyotrophic Lateral Sclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Amyotrophic Lateral Sclerosis Pipeline Drugs Market Overview

The symptoms of amyotrophic lateral sclerosis include difficulty breathing, difficulty swallowing, head drop due to weakness of the neck muscles, muscle cramps, speech problems, such as a slow or abnormal speech pattern (slurring of words), voice changes, hoarseness, weight loss.

The Amyotrophic Lateral Sclerosis pipeline drugs market research report provides comprehensive information on the therapeutics under development for Amyotrophic Lateral Sclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Amyotrophic Lateral Sclerosis and features dormant and discontinued projects.

Amyotrophic Lateral Sclerosis Pipeline Drugs Market Segmentation by Targets

The key targets in the Amyotrophic Lateral Sclerosis pipeline drugs market are TAR DNA Binding Protein 43, Superoxide Dismutase [Cu-Zn], Free Radical, Guanine Nucleotide Exchange C9orf72, Macrophage Colony Stimulating Factor 1 Receptor, 1 Phosphatidylinositol 3 Phosphate 5 Kinase, Apoptosis Regulator BAX, Kelch Like ECH Associated Protein 1, Ataxin 2, BDNF/NT 3 Growth Factors Receptor, and others.

Amyotrophic Lateral Sclerosis Pipeline Drugs Market Analysis by Targets

Amyotrophic Lateral Sclerosis Pipeline Products Market Analysis by Targets

For more target insights into the Amyotrophic Lateral Sclerosis pipeline Drugs market, download a free report sample

Amyotrophic Lateral Sclerosis Pipeline Products Market Segmentation by Mechanisms of Action

The key mechanisms of action in the Amyotrophic Lateral Sclerosis pipeline products market are TAR DNA Binding Protein 43 Inhibitor, Superoxide Dismutase [Cu-Zn] Inhibitor, Free Radical Scavenger, Guanine Nucleotide Exchange C9orf72 Inhibitor, 1 Phosphatidylinositol 3 Phosphate 5 Kinase Inhibitor, Apoptosis Regulator BAX Inhibitor, Kelch Like ECH Associated Protein 1 Inhibitor, BDNF/NT 3 Growth Factors Receptor Agonist, Glial Cell Line Derived Neurotrophic Factor Activator, Interleukin 10 Activator, and others.

Amyotrophic Lateral Sclerosis Pipeline Products Market Analysis by Mechanisms of Action

Amyotrophic Lateral Sclerosis Pipeline Products Market Analysis by Mechanisms of Action

For more mechanisms of action insights into the Amyotrophic Lateral Sclerosis pipeline products market, download a free report sample

Amyotrophic Lateral Sclerosis Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the Amyotrophic Lateral Sclerosis pipeline drugs market are oral, intravenous, intrathecal, subcutaneous, parenteral, intramuscular, sublingual, topical, inhalational, intraarticular, and others.

Amyotrophic Lateral Sclerosis Pipeline Drugs Market Analysis by Routes of Administration

Amyotrophic Lateral Sclerosis Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights into the Amyotrophic Lateral Sclerosis pipeline Drugs market, download a free report sample

Amyotrophic Lateral Sclerosis Pipeline Products Market Segmentation by Molecule Types

The key molecule types in the Amyotrophic Lateral Sclerosis pipeline products market are small molecule, gene therapy, cell therapy, monoclonal antibody, antisense oligonucleotide, synthetic peptide, recombinant protein, biologic, protein, antisense RNAi oligonucleotide, fusion protein, and others.

Amyotrophic Lateral Sclerosis Pipeline Products Market Analysis by Molecule Types

Amyotrophic Lateral Sclerosis Pipeline Products Market Analysis by Molecule TypesFor more molecule type insights into the Amyotrophic Lateral Sclerosis pipeline products market, download a free report sample

Competitive Landscape

Some of the leading players in the Amyotrophic Lateral Sclerosis pipeline drugs market are Biogen Inc, 1st Bio Therapeutics Inc, AcuraStem Inc, Denali Therapeutics Inc, Mitsubishi Tanabe Pharma Corp, Orpheris Inc, ProMIS Neurosciences Inc, PurMinds NeuroPharma Inc, QurAlis Corporation, and Treeway BV.

Amyotrophic Lateral Sclerosis Pipeline Drugs Market Analysis by Players

Amyotrophic Lateral Sclerosis Pipeline Products Market Analysis by Players

To know more about the leading players in the Amyotrophic Lateral Sclerosis pipeline drugs market, download a free report sample

Amyotrophic Lateral Sclerosis Pipeline Products Market Report Overview

Key Targets TAR DNA Binding Protein 43, Superoxide Dismutase [Cu-Zn], Free Radical, Guanine Nucleotide Exchange C9orf72, Macrophage Colony Stimulating Factor 1 Receptor, 1 Phosphatidylinositol 3 Phosphate 5 Kinase, Apoptosis Regulator BAX, Kelch Like ECH Associated Protein 1, Ataxin 2, BDNF/NT 3 Growth Factors Receptor, and Others
Key Mechanisms of Action TAR DNA Binding Protein 43 Inhibitor, Superoxide Dismutase [Cu-Zn] Inhibitor, Free Radical Scavenger, Guanine Nucleotide Exchange C9orf72 Inhibitor, 1 Phosphatidylinositol 3 Phosphate 5 Kinase Inhibitor, Apoptosis Regulator BAX Inhibitor, Kelch Like ECH Associated Protein 1 Inhibitor, BDNF/NT 3 Growth Factors Receptor Agonist, Glial Cell Line Derived Neurotrophic Factor Activator, Interleukin 10 Activator, and Others
Key Routes of Administration Oral, Intravenous, Intrathecal, Subcutaneous, Parenteral, Intramuscular, Sublingual, Topical, Inhalational, Intraarticular, and Others
Key Molecule Type Small Molecule, Gene Therapy, Cell Therapy, Monoclonal Antibody, Antisense Oligonucleotide, Synthetic Peptide, Recombinant Protein, Biologic, Protein, Antisense RNAi Oligonucleotide, Fusion Protein, and Others
Leading Players Biogen Inc, 1st Bio Therapeutics Inc, AcuraStem Inc, Denali Therapeutics Inc, Mitsubishi Tanabe Pharma Corp, Orpheris Inc, ProMIS Neurosciences Inc, PurMinds NeuroPharma Inc, QurAlis Corporation, Treeway BV, and Others

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Amyotrophic Lateral Sclerosis (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Amyotrophic Lateral Sclerosis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Amyotrophic Lateral Sclerosis (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Amyotrophic Lateral Sclerosis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Amyotrophic Lateral Sclerosis (Central Nervous System)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Amyotrophic Lateral Sclerosis (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

1st Bio Therapeutics Inc
2N Pharma ApS
4B Technologies (Suzhou) Co Ltd
4P-Pharma SAS
AB Science SA
Abbisko Cayman Limited
Above and Beyond Concierge Therapeutics LLC
AC Immune SA
Aclipse One Inc
Aclipse Therapeutics LLC
Actimed Therapeutics Ltd
AcuraStem Inc
Adare Pharma Solutions
Aeterna Zentaris Inc
AgoneX Biopharmaceuticals Inc
AI Therapeutics Inc
AL-S Pharma AG
Alector Inc
Alexion Pharmaceuticals Inc
Allife Medical Science and Technology Co Ltd
Alnylam Pharmaceuticals Inc
AlphaCognition Inc
Alsonex Pty Ltd
Amarna Therapeutics BV
Amicogen Inc
Amplo Biotechnology Inc
Amylyx Pharmaceuticals Inc
Anima Biotech Inc
Ankar Pharma SL
ANLBio Co Ltd
Annexon Inc
Apellis Pharmaceuticals Inc
Apic Bio Inc
Apogenix AG
Applied Genetic Technologies Corp
Aquilus Pharmaceuticals Inc
Aquinnah Pharmaceuticals Inc
AriBio
ArmaGen Inc
ArunA Bio Inc
Asahi Kasei Pharma Corp
Asdera LLC
Asha Therapeutics LLC
Ashvattha Therapeutics LLC
Astellas Pharma Inc
Astrogen Ltd
Athira Pharma Inc
Autotac Bio Inc
Avanir Pharmaceuticals Inc
AviadoBio Ltd
Avrion Therapeutics AG
BenevolentAI Ltd
BioArctic AB
Bioasis Technologies Inc
Biogen Inc
Biohaven Pharmaceutical Holding Company Ltd
Bioleaders Corp
Biolexis Therapeutics Inc
Biorchestra Co Ltd
Bisichem Co Ltd
Bloom Science Inc
BrainEver SAS
BrainStorm Cell Therapeutics Inc
Bruschettini Srl
Calico Life Sciences LLC
Capsida Biotherapeutics Inc
CavoGene LifeSciences
CellCure
Cellenkos Inc
Ceptur Therapeutics Inc
Cerion LLC
Chaperone Therapeutics Inc
Chemigen LLC
Chiesi Farmaceutici SpA
CholesteniX Ltd
Chronos Therapeutics Ltd
Clene Inc
Clevexel Pharma SA
Clinigen Ltd
Coave Therapeutics
Codiak BioSciences Inc
Cogentis Therapeutics Inc
Collaborative Medicinal Development LLC
Constant Therapeutics LLC
Corcept Therapeutics Inc
Corestem Inc
Coya Therapeutics Inc
Curatis AG
CuroNZ Ltd
Cytokinetics Inc
Daiichi Sankyo Co Ltd
Deargen Inc
Denali Therapeutics Inc
Dewpoint Therapeutics Inc
Disarm Therapeutics Inc
DR.Noah Biotech Inc
Eikonizo Therapeutics Inc
Eikonoklastes Therapeutics Inc
Eisai Co Ltd
Eledon Pharmaceuticals Inc
Eli Lilly and Co
Elixiron Immunotherapeutics Inc
Elysium Health Inc
EmendoBio Inc
Emerald Health Sciences Inc
ENCEFA
Enveda Biosciences Inc
Enzerna Biosciences LLC
Eolo Pharma
Everfront Biotech Inc
Exicure Inc
Expansion Therapeutics Inc
Expesicor Inc
Faze medicines
Foshan Rexie Biotechnology Co Ltd
Gene Therapy Research Institution Co Ltd
Generoath Co Ltd
Genervon Biopharmaceuticals LLC
Genetic Intelligence Inc
GeNeuro SA
Genuv Inc
Glialogix Inc
GlyTag LLC
GNT Pharma Co Ltd
Grifols SA
Grupo Ferrer Internacional SA
Guangzhou Magpie Pharmaceutical Co Ltd
Helixmith Co Ltd
Hemostemix Inc
Herantis Pharma Plc
Hope Biosciences LLC
Hopstem Biotechnology LLC
Iltoo Pharma
Immunity Pharma Ltd
ImmunoBrain Checkpoint Inc
ImmunoForge Co Ltd
Implicit Bioscience Ltd
ImStar Therapeutics Inc
InFlectis BioScience SAS
Inmune Bio Inc
InnoMedica Holding AG
InnoPharmaScreen Inc
Io Therapeutics Inc
Ionis Pharmaceuticals Inc
Iron Horse Therapeutics Inc
Jiangsu Ouwei Pharmaceutical Co Ltd
Junaxo Inc
Jupiter Neurosciences Inc
K Pharma Inc
K-Pax Pharmaceuticals Inc
Kadimastem Ltd
Keapstone Therapeutics Ltd
KeifeRx LLC
Klogene Therapeutics Inc
Knopp Biosciences LLC
Kringle Pharma Inc
Kyorin Pharmaceutical Co Ltd
Lascco SA
Lauren Sciences LLC
LifeSplice Pharma LLC
Locanabio Inc
Longboard Pharmaceuticals Inc
Maas Biolab
Maze Therapeutics Inc
MD Healthcare Inc
MedDay SA
MeiraGTx Holdings Plc
Merck & Co Inc
MetrioPharm AG
MetVital Inc
MimeTech Srl
Mitochon Pharmaceuticals Inc
Mitochondria In Motion Inc
Mitoconix Bio Ltd
MitoDys Therapeutics Ltd
Mitsubishi Tanabe Pharma Corp
NeuExcell Therapeutics Inc
Neugen Pharma Inc
Neuracle Genetics Inc
Neuracle Science Co Ltd
Neurevo GmbH
Neurimmune Holding AG
Neurodegeneration Therapeutics Inc
NeuroGenesis Ltd
Neuromagen Pharma Ltd
Neuropath Therapeutics Ltd
Neuroplast BV
Neuropore Therapies Inc
NeuroSense Therapeutics Ltd
Neurotune AG
Neuvivo Inc
Nevrox Ltd
New Biotic Inc
Newron Pharmaceuticals SpA
Nine Square Therapeutics Inc
Nobelpharma Co Ltd
Novartis AG
Novartis Gene Therapies
NovelMed Therapeutics Inc
NuNerve Pty Ltd
NysnoBio LLC
Oncocross Co Ltd
OptiKira LLC
Orchard Therapeutics Plc
Origami Therapeutics Inc
Orpheris Inc
Palisade Bio, Inc
Parnia Stem Cell Knowledge-Based Co
Pasithea Therapeutics Corp
Passage Bio Inc
Pfizer Inc
PharmaTher Holdings Ltd
PharmAust Ltd
PharmEnable Ltd
Pharnext SA
Plex Pharmaceuticals Inc
PRG S&Tech Inc
Priavoid GmbH
Prilenia Therapeutics Development Ltd
Projenx Inc
ProMIS Neurosciences Inc
Prosetta Biosciences Inc
Prothena Corp Plc
Prous Institute for Biomedical Research SA
PTC Therapeutics Inc
PurMinds NeuroPharma Inc
Q Therapeutics Inc
Q-State Biosciences Inc
QurAlis Corporation
Ra Pharmaceuticals Inc
Rapa Therapeutics LLC
RASRx LLC
Reata Pharmaceuticals Inc
ReceptoPharm Inc
Regulus Therapeutics Inc
reMYND NV
ReoStem LLC
ResQ Biotech
Retrotope Inc
Revalesio Corp
Sangamo Therapeutics Inc
SciNeuro Pharmaceuticals
Seelos Therapeutics, Inc.
Shanghai Pharmaceuticals Holding Co Ltd
Shanghai Zhimeng Biopharma Inc
Shinkei Therapeutics LLC
Sio Gene Therapies Inc
SOLA Biosciences LLC
Spedding Research Solutions SAS
Spinogenix Inc
Stealth BioTherapeutics Corp
Suzhou Auzone Biological Technology Co Ltd
Symbinas Pharmaceuticals Inc
Takara Bio Inc
Talon Pharmaceutical Services Inc
Tasly Biopharmaceuticals Co Ltd
Tempero Bio
Thera Neuropharma Inc
Theragen Etex Co Ltd
Theratome Bio Inc
TikoMed AB
Tranquis Therapeutics Inc
Transposon Therapeutics Inc
Treeway BV
Treventis Corp
Triplet Therapeutics Inc
Ultragenyx Pharmaceutical Inc
UniQure NV
Unity Biotechnology Inc
Vanqua Bio Inc
Vaxxinity Inc
VectorY Therapeutics Inc
Velvio GmbH
Verge Genomics
Viridian Therapeutics Inc
Voronoi Group
Voyager Therapeutics Inc
Wave Life Sciences Ltd
Wren Therapeutics Ltd
Xalud Therapeutics Inc
XellSmart Biomedical (Shanghai) Co Ltd
Xonovo Inc
Yantai YenePharma Co Ltd
Yumanity Therapeutics Inc
Zhittya Genesis Medicine Inc
ZZ Biotech LLC

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Amyotrophic Lateral Sclerosis – Overview

Amyotrophic Lateral Sclerosis – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Amyotrophic Lateral Sclerosis – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Amyotrophic Lateral Sclerosis – Companies Involved in Therapeutics Development

Amyotrophic Lateral Sclerosis – Drug Profiles

Amyotrophic Lateral Sclerosis – Dormant Projects

Amyotrophic Lateral Sclerosis – Discontinued Products

Amyotrophic Lateral Sclerosis – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Amyotrophic Lateral Sclerosis, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Amyotrophic Lateral Sclerosis – Dormant Projects, 2022

Amyotrophic Lateral Sclerosis – Discontinued Products, 2022

Amyotrophic Lateral Sclerosis – Discontinued Products, 2022 (Contd..1)

Figures

List of Figures

Number of Products under Development for Amyotrophic Lateral Sclerosis, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Amyotrophic Lateral Sclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,500

Can be used by individual purchaser only

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Amyotrophic Lateral Sclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Amyotrophic Lateral Sclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Amyotrophic Lateral Sclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.